Aditxt, Inc 8-K, filed Nov 13, 2020
Aditxt, Inc. (ADTX)
About this 8-K
Aditxt, Inc filed this 8-K on November 13, 2020.
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 13, 2020
Aditx Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-39336 | 82-3204328 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
2569 Wyandotte, St., Suite 101 Mountain View, CA |
94043 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (909) 488-0844
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock, par value $0.001 | ADTX | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02. | Results of Operations and Financial Condition. |
On November 13, 2020, Aditx Therapeutics Inc. (the “Company”) issued a press release with a business update and results for the quarter ended September 30, 2020. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such a filing, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
Exhibits
| Exhibit No. | Description | |
| 99.1 | Press release, dated November 13, 2020 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ADITX THERAPEUTICS, INC. | ||
| Date: November 13, 2020 | By: | /s/ Corinne Pankovcin |
| Corinne Pankovcin | ||
| Chief Financial Officer | ||
Exhibit 99.1
Aditxt Provides Business Update and Files Third Quarter 2020 10-Q
Mountain View, CA, Nov. 13, 2020 -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today provided a business update in conjunction with the filing of its Form 10-Q with the Securities and Exchange Commission.
Amro Albanna, Co-Founder and CEO of Aditxt, commented, “It’s been an exciting quarter for Aditxt that started with our successful IPO and Nasdaq listing in early July, followed several weeks later by a successful follow-on public offering. During the quarter we also added well-known industry names to our team and advisory board. Most importantly, we introduced the first application of our AditxtScore™ Monitoring platform, AditxtScore™ for COVID-19, for use in detecting antibodies against SARS-CoV-2 antigens, and for which we are awaiting a response from the U.S. Food and Drug Administration regarding the Emergency Use Authorization (EUA) application that we filed in August. As we’ve announced, we’re working hard to position the Company for commercialization of this product. We believe that Aditxt has accomplished much during its first quarter as a public company, and with cash of $13.7 million at September 30th to support the execution of our strategy, we are well positioned to achieve our goals for growth.”
For Aditxt’s complete financial results for the period ended September 30, 2020, see the Company’s quarterly report on Form 10-Q that was filed with the Securities and Exchange Commission on November 13, 2020.
About Aditx
Therapeutics
Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and
reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system.
The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce
tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information,
please visit: www.aditxt.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal
securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections,
outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product development;
the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding
product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects,
growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company.
Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated
by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the
section entitled “Risk Factors” in the Company’s prospectus, dated September 1, 2020, that was filed with the
Securities and Exchange Commission under File No. 333-248491, as well as discussions of potential risks, uncertainties, and other
important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All such statements speak
only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements,
whether as a result of new information, future events or otherwise.
Investor Relations:
PCG Advisory
Jeff Ramson
Chief Executive Officer
IR@aditxt.com
646-762-4518
www.aditxt.com